Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Eli Lilly wants the black market for one of its most promising obesity drugs shut down, and it’s turning to the courts to make that happen. The company announced six new lawsuits this week. Each one targets a business accused…
Eli Lilly entered June 2026 with something most pharmaceutical companies spend years chasing: clinical data so compelling that competitors can barely keep pace. At the American Diabetes Association’s annual Scientific Sessions, the company unveiled extended trial results for retatrutide. Clinicians,…
The world of weight management has completely transformed over the last few years. Groundbreaking GLP-1 medications are helping millions of people achieve profound, life-changing health improvements. Drugs like retatrutide, a newer triple-hormone medication, are taking these benefits even further. They…
Eli Lilly has an experimental drug called retatrutide, and it’s currently breaking records in late-stage clinical trials. In a recent study, patients with type 2 diabetes lost an average of 15.3% of their body weight over nine months. On top…
The medical world has seen a massive shift in how we treat obesity over the last ten years. For a long time, diet, exercise, and surgery were the only real tools available. Now, new medications are changing the game by…
The medical sector is currently undergoing a massive transformation in metabolic science in 2026. Scientists have developed a first-in-class triple agonist to treat individuals living with chronic weight issues. In view of this, the therapy engages three metabolic pathways to…